Noah Stansfield

NEXICART-2 has moved on to its expansion cohort after completing dosing of patients in its initial cohort.

Estrella noted that the patient had been diagnosed with follicular lymphoma grade 3A with high-risk 3B symptoms.

Daniel Hart, PhD, the senior director and head of technology development at Epic Bio, discussed potential applications of the new technology.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

CSF analyses from 7 patients treated in the study showed reductions of more than 80% in NAA levels from baseline.

Anixa noted that it had previously obtained clearance of a single-patient investigational new drug application to redose a patient in the trial.

The data, from the CARTITUDE-4 clinical trial, compared outcomes to patients treated with standard of care options.

The chief scientific officer and head of research, development, and Medical at Ocugen, also discussed future plans for the gene therapy, which is now in a phase 3 study.

The company pointed out that today, September 30, is LGMD Awareness Day.

John Brandsema, MD, a pediatric neurologist in the Division of Neurology at Children’s Hospital of Philadelphia, discussed several still-investigational drugs and therapies for DMD.

Enrollment difficulties were cited as the reason for discontinuing recruitment activities for KarMMa-9.

The approvals are indicated for patients 12 years and older.

Notably, today, September 26, is annually observed as Mesothelioma Awareness Day by the patient and clinician communities.

The chief scientific officer and head of research, development, and Medical at Ocugen, discussed OCU400, the company’s gene-agnostic gene therapy for IRDs.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

John Brandsema, MD, a pediatric neurologist in the Division of Neurology at Children’s Hospital of Philadelphia, discussed the complicated choice doctors, patients, and families now face with a wide range of treatment options available.

In lymph node biopsies from patients treated in the study, a mean exposure of 236,701 CAR T-cells per million across all dose levels was observed.

There were no SUSARS and no endophthalmitis observed among 29 patients treated in the study.

Kiromic anticipates that Deltacel-01's expansion portion, which is expected to include around 9 new patients, will begin screening patients before the end of September.

John Brandsema, MD, a pediatric neurologist in the Division of Neurology at Children’s Hospital of Philadelphia, discussed how Sarepta’s Elevidys has affected the landscape of care for DMD.

AAVB-081 is intended to address retinitis pigmentosa that results from Usher syndrome type 1B.

In honor of Usher Syndrome Awareness Day, CGTLive® interviewed Zheng-Yi Chen, DPhil, associate professor, Otolaryngology–Head and Neck Surgery, Harvard Medical School, about the current state of research in this rare disease.

Jeffrey Chamberlain, PhD, McCaw Endowed Chair of Muscular Dystrophy at University of Washington, shared his outlook on the trajectory of research in the field.

The pediatric neurologist in the Division of Neurology at Children’s Hospital of Philadelphia discussed several still-investigational drugs and therapies for DMD.

The product is currently being evaluated in a phase 1/1b clinical trial.

The single-arm trial enrolled 12 male patients in total across the United States and European Union.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

The pediatric neurologist in the Division of Neurology at Children’s Hospital of Philadelphia discussed the complicated choice doctors, patients, and families now face with a wide range of treatment options available.

Jeffrey Chamberlain, PhD, McCaw Endowed Chair of Muscular Dystrophy at University of Washington, highlighted studies presented at MDA's 2024 conference.

VNX-101 is intended to transduce cells of the liver, causing them to express a transgene coding for a bispecific T-cell engager.